Denosumab for Prevention of Post-Teriparatide Bone Loss in Premenopausal Women With IOP

Completed · Phase 2

Conditions studied: Adult Idiopathic Generalized Osteoporosis

In brief

The purpose of this research study is to evaluate antiresorptive therapy with denosumab (Prolia) for prevention of bone loss after stopping teriparatide (TPTD) in premenopausal women with idiopathic osteoporosis. Premenopausal women who have received TPTD in the FDA Orphan Diseases Program-funded trial, "A Phase 2 Study of Teriparatide for the Treatment of Idiopathic Osteoporosis in Premenopausal Women" (NCT01440803) may be eligible to participate in the current study, a 36-month open-label pilot study of denosumab (Prolia®, 60mg subcutaneous (SC) every 6 months). The goals of the study are to estimate the effects of denosumab on central and peripheral, as well as trabecular and cortical, bone mass and microstructure and to obtain preliminary data to inform the design of a future randomized study. This study presents the first opportunity to study the effects of denosumab after TPTD in this unique and severely affected group of young women. Funding Source: FDA Office of Orphan Products Development (OOPD).

Key facts

Study ID

NCT02049866

Run by

Elizabeth Shane

People needed

33

Starts

2014-11-19

Expected to finish

2021-12-23

Last updated by the study team

2022-12-12

Who can join

Age: 20 and older, up to 50. Sex: female. Healthy volunteers: not accepted.

You may qualify if…

• All women completing NCT01440803 who remain without a disease or medication that causes osteoporosis will be offered enrollment into this study.
• (Premenopausal status is no longer be required for entry.)

You may not qualify if…

• Renal insufficiency or liver disease: Creatinine, transaminase (AST)/alanine transaminase (ALT) above upper limit of normal
• Vitamin D deficiency: 25-hydroxyvitamin D (25-OHD) <30 ng/mL
• Pregnancy: urine pregnancy test must be negative

Where it is running

• Creighton University — Omaha, Nebraska, United States
• Columbia University Medical Center — New York, New York, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.